Answers are grounded in this paper and cite their sources.
Ciltacabtagene autoleucel (cilta-cel) is a B cell maturation-antigen-targeting chimeric antigen receptor (CAR) T cell product approved for relapsed/refractory multiple myeloma treatment. Previously reported cases of post-cilta-cel immune effector cell enterocolitis (IEC-EC) have been described as a severe diarrhea associated with clonal CAR T cell populations. Here we report nine cases of cilta-cel-associated IEC-EC with CAR T cell-positive (CAR + ) infiltration in 158 cilta-cel-treated patients at MD Anderson Cancer Center (incidence of 5.1% at a 6-month landmark and 5.7% globally). Cilta-cel infiltration was the primary cause of IEC-EC, and all cases demonstrated monoclonal or oligoclonal T cell populations as measured by vector integration analysis, flow cytometry and T cell receptor sequencing. Patients with IEC-EC had 100-fold more CAR T cell persistence in the peripheral blood than patients without IEC-EC. RNA sequencing analysis revealed increased cytotoxic and inflammatory programs associated with the CAR + infiltrates relative to controls. Clonal vector integration occurred in introns of highly expressed genes without evidence of vector-mediated mutagenesis. Candidate driver mutations were sparse and heterogeneous, distinguishing IEC-EC from peripheral T cell lymphoma following CAR T cell therapy. In sum, we find that IEC-EC pathology represents a distinct, duodenum-predominant, clonal lymphoproliferative disorder characterized by the infiltration of clonal CAR + cytotoxic T cells into the gastrointestinal tract.
No takes yet. Share an insight, caveat, or question.
Sainz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: